Business
Investor Presentation via Investor Meet Company
Investor Presentation via Investor Meet Company.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n22 September 2023\n \nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nInvestor Presentation via Investor Meet Company\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that CEO Ajan Reginald and Chairman Stephen West will give a live presentation via the Investor Meet Company platform at 10am BST on Wednesday, 27 September 2023. The objective of the presentation will be to provide investors with an update relating to the Company's Interim Results.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and can arrange to meet ROQUEFORT THERAPEUTICS via:\nhttps://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor\nInvestors who already follow ROQUEFORT THERAPEUTICS PLC on the Investor Meet Company platform will automatically be invited.\nENDS\nEnquiries:\n\n\n\nRoquefort Therapeutics plc\n\n\n\n\nStephen West (Chairman) / Ajan Reginald (CEO)\n\n\n+44 (0)20 3918 8633\n \n\n\n\n\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\n \nOptiva Securities Limited (Joint Broker)\n\n\n \n+44 (0)203 764 2341\n\n\n\n\nChristian Dennis\n \nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n \n\n\n+44 (0)20 3411 1881\n \n \n+44 (0)20 7466 5000\n \n\n\n\n \nLEI: 254900P4SISIWOR9RH34\n \nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\n \nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\n&n...